A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) is estimated to become the second leading cause of cancer-related deaths by 2030 with mortality rates of up to 93%. Standard of care chemotherapeutic treatment only prolongs the survival of patients for a short timeframe. Therefore, it is important to understand events driving treatment failure in PDAC as well as identify potential more effective treatment opportunities. PDAC is characterized by a high-density stroma, high interstitial pressure and very low oxygen tension. The aim of this study was to establish a PDAC platform that supported the understanding of treatment response of PDAC organoids in mono-, and co-culture with pancreatic stellate cells (PSCs) under hypoxic and normoxic conditions. Cultures were exposed to Gemcitabine in combination with molecules targeting relevant molecular programs that could explain treatment specific responses under different oxygen pressure conditions. Two groups of treatment responses were identified, showing either a better effect in monoculture or co-culture. Moreover, treatment response also differed between normoxia and hypoxia. Modulation of response to Gemcitabine was also observed in presence of a Hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor and HIF inhibitors. Altogether this highlights the importance of adjusting experimental conditions to include relevant oxygen levels in drug response studies in PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Fig. 5 Effect of hypoxia and hypoxia-mimicking compounds on PDAC response to treatment. A PDAC organoids were grown in monoculture and co-culture with PSCs under normoxic and hypoxic conditions. The cells were grown for 4 days on the OrganoPlate® and subjected to 1 µM Gemcitabine and 1 µM Roxadustat for 72 h, before their survival was analyzed with Cell Titer Glo 3D viability assay. The graph shows the survival of the organoids normalized to a no-treatment control (=medium only). 0.1% DMSO was used as a vehicle control and showed no effect on the cells. The data was compared with Ordinary one-way ANOVA and Tukey’s multiple comparison test and shown are mean and SD (****p ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05). B Diagram showing key regulators of HIF1α in hypoxia and normoxia. During normoxia HIF1α is constantly hydroxylated by prolyl hydroxylases (PHDs), that use oxygen (O2) and iron (Fe2+), thus leading to subsequent ubiquitination and proteasomal degradation of HIF1α. In contrast, under hypoxia or due to hypoxia mimicking factors (such as Roxadustat treatment), PHDs are inhibited, thus enabling the HIF1α subunit to bind to the HIF1β subunit. This HIF-complex can migrate to the nucleus, bind a hypoxia responsive element (HRE), and lead to the activation of several genes involved in angiogenesis, glycolysis, proliferation, and survival [42]. C Caspase 3/7 staining of chips in hypoxia was compared to chips in normoxia to show respective areas of apoptosis. D Quantification of the Caspase 3/7 assay staining depicting mono-, and co-cultured cells in normoxia and hypoxia when treated with Gemcitabine or Gemcitabine with Roxadustat. The data was compared with Ordinary one-way ANOVA and Tukey’s multiple comparison test and shown are mean and SD (****p ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05), (n = 3, N = 2). E Reactive Oxygen Species (ROS) staining with ROS marker, Hoechst for nuclei staining and Propidium Iodide (PI) for dead cell staining in PDAC monoculture. F Quantification of ROS intensity to the total cell count in hypoxia samples was normalized to normoxia samples comparing untreated samples with samples treated with Gemcitabine with or without Roxadustat. G Monocultures treated with 500 nM Gemcitabine (G), 1 uM Roxadustat (R), 1 nM Echinomycin (E) and 10 uM Kc7f2 (K). H Co-cultures treated with 500 nM Gemcitabine (G), 1 uM Roxadustat (R), 1 nM Echinomycin (E) and 10 uM Kc7f2 (K) to determine the effect of HIF-inhibitors on PDAC treatment. Shown are mean and SD (****p ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05), (N = 3, n = 3). The data was analyzed with two-way ANOVA and Sidak’s multiple comparison test. Shown are maximum projections (10× magnification) of PDAC monoculture for all images, imaged on the ImageXpress Micro Confocal (Molecular Devices, US). Scale Bar = 200 um.](https://figures.cochat.ai/paper-figures/deb3e4ac82dd4a9896b15b1defa42f99/a-microfluidic-based-pdac-organoid-system-reveals-the-impact-of-hypoxia-in-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several research teams are currently combining two advanced in vitro technologies—organoid cultures and tumor-chip systems—to develop innovative organotypic models for improved patient stratification and therapeutic decision-making in PDAC (Narayanan et al., 2021; Osuna De La Peña et al., 2021; Geyer et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Geyer et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Positive feedback between oncogenic KRAS and HIF-1α confers drug resistance in colorectal cancer
Sun, W.-B., Wang, Y., Lei, F., Rong, W., & Zeng, Q. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s80017 · Cited by 29
RetractedIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Together these studies support the notion that hypoxic tumors have an increased metastatic potential, chemoresistance and a consequent poor prognosis [16].”
BackgroundÖzdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
Cancer as an overhealing wound: an old hypothesis revisited
Schäfer, M., & Werner, S. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2455 · Cited by 956
Weidemann, A., & Johnson, R. S. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.12 · Cited by 941 · cited 1×
“Other studies have shown that HIF activation maintains low ROS levels in response to suppression of the TCA cycle during hypoxia in some cell types, which is what we observe in PDAC organoid monocultures [41].”
BackgroundOrgan-on-a-chip: recent breakthroughs and future prospects
Wu, Q., Liu, J., Wang, X., Feng, L., Wu, J., Zhu, X., Wen, W., & Gong, X. (2020) · BioMedical Engineering OnLine · doi:10.1186/s12938-020-0752-0 · Cited by 701
Pancreatic tumors show high levels of hypoxia
Koong, A. C., Mehta, V. K., Le, Q. T., Fisher, G. A., Terris, D. J., Brown, J. M., Bastidas, A. J., & Vierra, M. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00803-8 · Cited by 650
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508
Cited by
Thorel, L., Perréard, M., Florent, R., Divoux, J., Coffy, S., Vincent, A., Gaggioli, C., Guasch, G., Gidrol, X., Weiswald, L.-B., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01272-5 · Cited by 236
Choi, D., Gonzalez‐Suarez, A. M., Dumbravă, M., Medlyn, M. J., de Hoyos‐Vega, J. M., Cichocki, F. M., Miller, J. S., Li, D., Zhu, M., Stybayeva, G., et al. (2023) · Advanced Science · doi:10.1002/advs.202303088 · Cited by 85
Revolutionizing immune research with organoid-based co-culture and chip systems
Papp, D., Korcsmáros, T., & Hautefort, I. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae004 · Cited by 75
Advances in Microfluidic Technologies in Organoid Research
Liu, H., Gan, Z., Qin, X., Wang, Y., & Qin, J. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302686 · Cited by 74
Han, X., Burrows, M., Kim, L. C., Xu, J. P., Vostrejs, W., Le, T. N. V., Poltorack, C. D., Jiang, Y., Cukierman, E., Stanger, B. Z., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114972 · Cited by 61
Metadata
- Authors
- Geyer, M., Schreyer, D., Gaul, L.-M., Pfeffer, S., Pilarsky, C., & Queiroz, K.
- Affiliations
- Mimetas (Netherlands) (NL)
- University of Glasgow (GB)
- Universitätsklinikum Erlangen (DE)
- Corresponding author
- Geyer, Marlene
- Venue
- Cell Death Discovery
- Published
- 2023-01-21
- Volume
- 9
- Issue
- 1
- Pages
- 20-20
- ISSN
- 2058-7716 (ISSN-L)
- PMC
- PMC9867742
- OpenAlex
- W4317662148
- Cited by
- 61
- References
- 41
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 18 · 2023: 7
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death Discovery (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- EC | Horizon 2020 Framework Programme (861196)
- Ministerie van Economische Zaken (IK17088)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- pancreatic ductal adenocarcinoma, organoids, hypoxia, pancreatic stellate cells, gemcitabine, treatment response, co-culture, microfluidics, hypoxia-inducible factor, prolyl hydroxylase inhibitors, HIF inhibitors, tumor microenvironment, drug response
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment. https://app.cochat.ai/papers/10.1038/s41420-023-01334-z
- The paper
- Geyer, M., Schreyer, D., Gaul, L.-M., Pfeffer, S., Pilarsky, C., & Queiroz, K. (2023). A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment. Cell Death Discovery. https://doi.org/10.1038/s41420-023-01334-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.